GLP-1 and Non-exercise Activity Thermogenesis in RHZ

NCT01638260 on ClinicalTrials.gov · last registry update 2013-12-17

Stopped early, having planned 22 participants. The sponsor logged completion for November 2013. Primary outcome, as filed: Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Maastricht University Medical Center
Sponsor type: Other
Enrollment: 22
Started: 2012-10
Primary completion: 2013-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.